$TWST

Green Paula sold $1.9M of TWST

Green Paula (SVP of Human Resources) sold 10,088 shares of Twist Bioscience Corp (TWST) at $188.88 ($1.91M total) on 2026-10-02.

Original reporting
SEC EDGAR · Green Paula
Published Oct 5, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a negative signal, though the amount is modest relative to total shares.

02

Market read

Provides fresh insider transaction data for traders monitoring TWST.

03

What to watch

Absence of a 10b5-1 plan and the insider's role in HR may limit signaling value.

Relevance 6/10Novelty 5/10Timing: after market close on filing day

Background

Twist Bioscience filed a Form 4 reporting an insider sale by its SVP of Human Resources.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

Form 4 shows SVP of HR sold 10,088 shares for $1.9M, reducing insider stake.

Expected impact

likely downward pressure as market prices the insider sell.

Evidence & confidence

Sale size is modest but notable for a senior HR officer; no 10b5-1 plan suggests discretionary sell.

Market effects

Minimal impact on biotech sector; insider sales are common.

No regional effect.

Limited to investors tracking Twist Bioscience.

Counterpoint

The sale could be unrelated to company outlook, merely personal liquidity need.

Key entities

  • Twist Bioscience Corp

    Biotech company listed on NASDAQ.

  • Green Paula

    SVP of Human Resources, insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.